Consensus Veru Inc.

Equities

VERU

US92536C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
1.23 ^USD	-3.15%		-6.82%	+70.83%

May. 22	Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	CI
May. 14	B. Riley Securities Starts Very With Buy Rating, $5 Price Target	MT

Evolution of the average Target Price on Veru Inc.

Price target over the last 5 years

History of analyst recommendation changes

7194336feed56cbc7cdfb5213eef6e7.Hs-S80Rj_3TXlGpdjsLj9A9KoOTey3XNtZ7tWAGM2DQ.Tb36oxE1iziPuS4TxZe3wD9n6N25-k231_SdPVn2k1Fs_PSeMi-2EODsMw~a5a49fa166818c8bf7ea173e49e05e8b

Analyst Recommendations on Veru Inc.

B. Riley Securities Starts Very With Buy Rating, $5 Price Target	May. 14	MT
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	May. 06	MT
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT
Raymond James Starts Very With Outperform Rating, $3 Price Target	Mar. 28	MT
Oppenheimer Adjusts Veru Price Target to $7 From $9, Maintains Outperform Rating	23-08-14	MT
HC Wainwright Adjusts Price Target on Veru to $2 From $6, Maintains Buy Rating	23-05-15	MT
HC Wainwright Lowers Veru's Price Target to $6 From $14, Keeps Buy Rating	23-04-06	MT
Oppenheimer Adjusts Veru Price Target to $9 From $14, Maintains Outperform Rating	23-03-15	MT
Atlanta Fed President's Comments on Rate Hikes Continue to Boost Sentiment, Driving Cautious Gains for US Equity Futures	23-03-03	MT
Oppenheimer Adjusts Veru's Price Target to $14 From $20, Maintains Outperform Rating	23-02-14	MT
HC Wainwright Adjusts Price Target on Veru to $14 From $18, Maintains Buy Rating	23-02-10	MT
HC Wainwright Lowers Price Target on Veru to $18 From $21, Maintains Buy Rating	22-12-07	MT
HC Wainwright Cuts Price Target on Veru to $21 from $24, Keeps Buy Rating	22-11-10	MT
FDA staff flags several uncertainties with Veru's COVID-19 drug	22-11-07	RE
Cantor Fitzgerald Adjusts Veru's Price Target to $30 From $24, Reiterates Overweight Rating	22-08-12	MT
Brookline Capital Markets Adjusts Price Target for Veru to $31 From $29, Reiterates Buy Rating	22-05-18	MT
Jefferies Financial Raises Veru's Price Target to $55 From $33, Maintains Buy Rating	22-05-13	MT
HC Wainwright Adjusts Veru's Price Target to $24 from $21, Keeps Buy Rating	22-04-12	MT
Oppenheimer Adjusts Veru's Price Target to $36 From $25, Maintains Outperform Rating	22-04-12	MT
Oppenheimer Adjusts Veru Price Target to $25 From $26, Maintains Outperform Rating	22-02-10	MT
Veru : Says Phase 1b/2 Trial of Sabizabulin in Prostate Cancer Shows Overall Response Rate of 21%	21-09-20	MT
VERU : Oppenheimer Adjusts Veru PT to $26 From $24, Maintains Outperform Rating	21-08-13	MT
VERU : Jefferies Starts Veru at Buy with $19 Price Target	21-04-13	MT
VERU : Oppenheimer Adjusts Veru PT to $24 From $19, Maintains Outperform Rating	21-02-11	MT
VERU : HC Wainwright & Co. Adjusts Price Target on Veru to $22 From $17, Maintains Buy Rating	21-02-11	MT